Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 20, 2004. The report primarily discloses changes in director interests related to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions within a retirement plan.
- Share Price: $44.85 per share (transaction date January 16, 2004) and $44.55 per share (average price for prior movement).
- Plan Holdings: Fluctuated between approximately 18.65 million and 18.71 million Ordinary Share ADRs.
Material Changes
The filing details movements in the GlaxoSmithKline US Retirement Savings Plan affecting the potential interests of Directors Dr. J.P. Garnier and Dr. T. Yamada:
- Decrease: On January 15, 2004, the fund's holdings decreased from 18,658,782 to 18,651,236 ADRs.
- Increase: On January 16, 2004, the fund's holdings increased from 18,651,236 to 18,713,521 ADRs.
- Direct Interest: Specific increases in direct interests were noted for Dr. J.P. Garnier (78 shares) and Dr. T. Yamada (37 shares) on January 16, 2004.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of director shareholding changes.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of the latest reporting date.
- Confirm the specific direct shareholdings of Dr. J.P. Garnier and Dr. T. Yamada outside of the discretionary fund.
- Review the pricing of the ADRs ($44.55 vs $44.85) to understand market volatility during the transaction window.